chemotherapy Articles
-
Building personalized treatment plans for early-stage colorectal cancer patients
Abstract We developed a series of models to predict the likelihood of recurrence and the response to chemotherapy for the personalized treatment of stage I and II colorectal cancer patients. A recurrence prediction model was developed from 235 stage I/II patients. The model successfully distinguished between high-risk and low-risk groups, with a hazard ratio of recurrence of 4.66 (p < ...
-
Morbidity pattern of pulmonary tuberculosis and housing quality in Lagos metropolis, Nigeria
The intractable problem of tuberculosis (TB) control despite advances in chemotherapy requires additional research effort to unravel the pertinent factors that make the disease preponderant in developing countries. The present study examined the pattern of TB morbidity in Lagos metropolis with the aim of identifying the explanatory factors. Data on reported cases of pulmonary TB were collected ...
-
Advancing patient care for Japan`s most common cancer - Case Study
Challenge Calculating the appropriate sample size for a first of its kind stage-II colon cancer trial As Chairman of the Department of Biostatistics, Professor Satoshi Teramukai leads a variety of investigator-initiated clinical trials at the Kyoto Prefectural University of Medicine. With over 35 years experience, hundreds of published papers and thousands of citations, Professor Satoshi ...
By Statsol
-
Nanopharmaceuticals II: application of nanoparticles and nanocarrier systems in pharmaceutics and nanomedicine
The principle aim of using nanoparticles in pharmaceutical delivery systems is to enable targeted and efficient delivery of the appropriate levels of therapeutic or diagnostic agents to the target sites with reduced, if any, side effects to the patient. Given the benefits that nanotechnology offers, much effort has focused on producing nanoparticles for the delivery of drugs (particularly ...
-
Defining Oncology and Aging
Cancer survival rates decrease with age, in part because the efficacy of cancer therapies declines in older individuals. Chemotherapy and radiotherapy wreak havoc on the immune system, kill both healthy and cancerous cells alike and cause a buildup of cellular waste in the tissue. This residual waste needs to be either removed from the body or efficiently restored to its original ...
-
The development of complete personalized treatment plans for colon cancer patients utilizing three gene prediction models.
Background Combination chemotherapy using fluorouracil, leucovorin with or without oxaliplatin (5-FU and FOLFOX) are standard treatment for locally advanced colon cancer. However, about half of the patients developed recurrence. The objective of this study was to use gene profiling to predict treatment efficacy for colon cancer patients (stages 1-3). We developed three prediction models: the ...
-
Reactive oxygen species regulate hypoxia-inducible factor 1 differentially in cancer and ischemia
In exercise, as well as cancer and ischemia, hypoxia-inducible factor 1 (HIF1) transcriptionally activates hundreds of genes vital for cell homeostasis and angiogenesis. While potentially beneficial in ischemia, upregulation of the HIF1 transcription factor has been linked to inflammation, poor prognosis in many cancers, and decreased susceptibility of tumors to radiotherapy and chemotherapy. ...
-
Reactive oxygen species regulate hypoxia-inducible factor 1 differentially in cancer and ischemia
In exercise, as well as cancer and ischemia, hypoxia-inducible factor 1 (HIF1) transcriptionally activates hundreds of genes vital for cell homeostasis and angiogenesis. While potentially beneficial in ischemia, upregulation of the HIF1 transcription factor has been linked to inflammation, poor prognosis in many cancers, and decreased susceptibility of tumors to radiotherapy and chemotherapy. ...
-
Bilateral Insufficiency Fractures in an Oncology Patient Treatment with the CurvaFix IM System - Case Study
CASE PRESENTATION A 70-year-old female recently diagnosed with metastatic pancreatic cancer presented with acute new onset of lower back pain. The patient was taking chemotherapy, participating in a drug therapy trial, and had received radiation therapy. There was no history of acute trauma to the pelvic or acetabular region. Magnetic resonance imaging revealed bilateral fragility fractures, with ...
-
Liposomes in Anti-tumour Drug Carriers
Introduction Chemotherapy with anti-tumor agents is currently one of the most important systemic treatments for cancer. However, direct treatment with drugs lacks specificity and sensitivity and tends to attack normal cells indiscriminately, resulting in side effects. Liposomes, as drug carriers, provide a superior solution for maintaining or enhancing the efficacy of chemotherapy while reducing ...
By BOC Sciences
-
Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling
Abstract Ovarian carcinoma is a leading cause of gynecologic cancer death in women. Despite treatment, a large number of women with ovarian cancer eventually relapse and die of the disease. Hence, recurrent ovarian cancer continues to be a therapeutic dilemma, possibly a result of the emergence of drug resistance during relapse. Recent advances in expression genomics enable global transcript ...
-
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer ...
-
Comparison and Analysis of SMDC, ADC, and DAC
In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the therapeutic index while providing selective delivery. What are their similarities and differences? What are their respective advantages? What is the current status of ...
By BOC Sciences
-
A Reflection on Blood Cancer Awareness Month: Patient Spotlight
As September and Blood Cancer Awareness Month wrap up, we want to reflect on a memorable conversation with Karen Thomas, a woman who received clonoSEQ® testing, and her physician, Dr. Hazma Hashmi, a hematologist-oncologist from the Medical University of South Carolina. At Adaptive, we know our diagnostic tests provide key information that help physicians and patients make treatment ...
-
Intracranial Neoplasms: The Evolution of Radiotherapies
CURRENT STANDARD OF CARE FOR BRAIN TUMORS The current initial standard of care for aggressive brain tumors—whether they are primary brain tumors (ie, tumors that originate in the brain), or metastatic tumors from cancers that started outside of the brain—is resection. After surgery, a follow-up treatment, also referred to as adjuvant treatment, is often recommended to help eliminate ...
-
Philly Pharmacologists are Developing a Promising Pain-Relieving CBD Analog Drug
Scientists from Temple’s Lewis Katz School of Medicine and local biopharma company Neuropathix are testing their compound, KLS-13019, which is intended to target chemotherapy-induced pain in cancer patients. Sara Jane Ward, assistant professor of pharmacology at Temple University’s Lewis Katz School of Medicine, and Douglas Brenneman, chief pharmacologist at Neuropathix, discuss ...
-
Temple research finds that tweaking CBD may help it curb pain and opioid use in mice
Doylestown-based Neuropathix is running safety tests required to start clinical trials in humans. The compound may help with neuropathy, a severe type of chronic pain associated with cancer treatment. The next generation of cannabis-inspired medicine might be grown in test tubes instead of greenhouses. Researchers at Temple University have partnered with Doylestown-based pharmaceutical company ...
-
The 3rd AIDS patient is "cured"! Has mankind finally conquered AIDS?
At an academic conference on Feb 15, U.S. experts announced the world's first female AIDS "cure," making it the third case of HIV infection to be cured. After therapy and withdrawal of antiviral drugs, HIVs were not identified in the patient's body for more than 14 months, indicating that the virus was in complete remission, according to academics. The key to this patient's recovery was a blood ...
-
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system ...
-
Introduction of Chitosan as Nano-drug Delivery Carrier
Chitin is the second largest natural polymer after cellulose, and it exists widely in nature, such as shells of crustaceans such as shrimps, crabs, insects, and cell walls of fungi. Although chitin has good biocompatibility and biodegradability, its poor solubility limits its practicality in the field of biomedicine. The product of chitin deacetylation is chitosan. Chitosan is structurally ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you